REGN
Regeneron Pharma (REGN)
NASDAQ
$957.03+$1.56 (+0.16%)
Price as of Nov 13, 2026 7:55 PM EST
  • $96.7B
    Market Cap
  • 38.48%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: 41
  • Momentum Score: 38
  • True Yield: N/A
  • Financial Health Score: 10
TradeSmith Loading

Latest Research & News

Better Biotech ETF: First Trust's FBT vs. Invesco's PBE

First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.

11/14/2026, 3:04 PM • The Motley Fool

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

11/14/2026, 7:05 AM • The Motley Fool

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.

11/12/2026, 1:00 PM • GlobeNewswire

Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's newly FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP). The company will provide patient access support, infusion services, and clinical coordination through its SoleoRare® division, leveraging its expertise in ultra-rare diseases.

11/10/2026, 7:00 AM • GlobeNewswire

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.

11/08/2026, 4:32 PM • The Motley Fool

Regeneron: 3 Key Takeaways for Long-Term Investors

Regeneron reported Q3 2026 revenue of $5.1 billion with 36% year-over-year growth. Key drivers include Dupixent reaching record sales of $6.5 billion (up 35% YoY), EYLEA HD expanding rapidly with U.S. sales of $699 million (up 62%), and promising early-stage liver disease therapy showing 70% fat reduction in 12 weeks. The company plans to increase research spending by mid-teens percentage in 2027 to fund 15 late-stage clinical trials.

10/31/2026, 10:49 AM • The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the failure of its DURAVYU drug candidate to meet primary efficacy endpoints in two Phase 3 clinical trials (LUGANO and LUCIA) for wet AMD treatment. The company's stock plummeted 66.98% on August 17, 2026, and an additional 85.28% on October 19, 2026, following the disappointing results. EyePoint announced significant cost-cutting measures including a 53% workforce reduction and termination of its wet AMD clinical program.

10/27/2026, 5:58 PM • GlobeNewswire

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharmaceuticals has extended its agreement with BARDA to supply additional doses of Inmazeb, its FDA-approved Ebola treatment, through 2031 for approximately $270 million. The company is also advancing maftivimab, a component of Inmazeb, as a potential monotherapy treatment for Bundibugyo virus disease in the current outbreak in the Democratic Republic of the Congo.

10/26/2026, 7:00 AM • GlobeNewswire

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron announced longer-term data (44-month follow-up) from the Phase 3 C-POST trial showing Libtayo (cemiplimab) as adjuvant treatment for high-risk cutaneous squamous cell carcinoma demonstrated a 37% reduction in risk of death compared to placebo, with sustained disease-free survival benefits. The drug was approved by the FDA in October 2025 and European Commission in November 2025 as the first immunotherapy for this indication.

10/25/2026, 5:15 AM • GlobeNewswire

Facing Investing Fears

A Motley Fool podcast discusses how historical S-1 risk factors from Amazon, Alphabet, and Meta didn't materialize into existential threats, offering perspective on Anthropic's alarming AI risks. The hosts identify stocks hitting new lows amid market fear—including Brookfield Corporation, Shopify, and Realty Income—while explaining how rising bond yields create both challenges for growth stocks and opportunities for cash-rich businesses and financial institutions.

10/23/2026, 10:29 AM • The Motley Fool

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.

10/19/2026, 10:24 AM • The Motley Fool

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.

10/17/2026, 3:24 PM • The Motley Fool

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved cancer indications. The new regimen allows for extended dosing of 700 mg every six weeks after an initial 12-week treatment with 350 mg every three weeks, and optional reduction of infusion time to 15-30 minutes. The European Commission is expected to make a final decision in the coming months.

10/16/2026, 7:00 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

10/06/2026, 5:36 PM • GlobeNewswire

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Regeneron announced presentations of new clinical research at ESMO Congress 2026, highlighting late-breaking Phase 3 data for Libtayo (cemiplimab) in cutaneous squamous cell carcinoma, Phase 2 neoadjuvant treatment data, and new research on Factor XI antibodies for cancer-associated thrombosis. The company is presenting 10 abstracts covering trials in CSCC, NSCLC, ovarian cancer, melanoma, and cancer-associated thrombosis.

10/06/2026, 7:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$942.00
$961.94
$955.47
1-Year Range
$600.66
$973.36
$955.47
Latest Close$955.47
Change
+$4.28 (+0.45%)
Volume1,165,718
Market Cap$96.7B
Shares Outstanding101.6M
P/E (TTM)21.16
Diluted EPS (TTM)$45.15
Enterprise Value$95.0B

Information as of 11/13/2026

Company Profile

REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS INC
https://www.regeneron.com
$96.7B
Market Cap
$4.8B
Net Income
Sector: Healthcare
Industry: Biotechnology
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
914 847 7000

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Key Executives

  • Leonard S. Schleifer
  • George D. Yancopoulos
  • Joseph J. LaRosa
  • Daniel Van Plew
  • Andrew J. Murphy

Current Ownership Distribution

  • Mutual Funds2.4B (57.03%)
  • Institutions1.8B (42.56%)
  • Insiders17.7M (0.42%)
  • Other0 (0.00%)